The short version of lipolysis fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-08-14. Anything still debated is marked as such rather than presented as settled.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Seborrhoeic dermatitis or seborrheic dermatitis (depending upon the variety of English used) is a long-term skin disorder. Symptoms include flaky, scaly, greasy, and occasionally itchy and inflamed skin. Areas of the skin rich in oil-producing glands are often affected including the scalp, face, and chest. It can result in social or self-esteem problems. In babies, when the scalp is primarily involved, it is called cradle cap. Mild seborrhoeic dermatitis of the scalp may be described in lay terms as dandruff due to the dry, flaky character of the skin. As dandruff may refer to any dryness or scaling of the scalp, not all dandruff is seborrhoeic dermatitis. Seborrhoeic dermatitis is sometimes inaccurately referred to as seborrhoea. The cause is unclear but believed to involve a number of genetic and environmental factors. Risk factors for seborrhoeic dermatitis include poor immune function, Parkinson's disease, and alcoholic pancreatitis. The condition may worsen with stress or during the winter. Malassezia yeast is believed to play a role. It is not a result of poor hygiene. Diagnosis is typically clinical and based on the symptoms present. The condition is not contagious. The typical treatment is topical antifungal cream and anti-inflammatory agents. Specifically, ketoconazole or ciclopirox are effective. Seborrhoeic dermatitis of the scalp is often treated with shampoo preparations of ketoconazole, zinc pyrithione, piroctone olamine and selenium disulfide.
A common term in New England, especially Connecticut, Massachusetts, and Rhode Island is grinder; its origin has several possibilities. One theory says it is derived from Italian-American slang for a dock worker, among whom the sandwich was popular. Others say that it was called a grinder because the bread's hard crust required much chewing, and that it would grind one's teeth. In Pennsylvania, New York, and parts of New England, the term grinder usually refers to a hot submarine sandwich (meatball, sausage, etc.), whereas a cold sandwich (e.g., cold cuts) is usually called a "sub". In the Philadelphia area, the term grinder is also applied to any hoagie that is toasted in the oven after assembly, whether or not it is made with traditionally hot ingredients.
Claude Bosi and his wife Claire opened Hibiscus in Ludlow, Shropshire, in 2000. The location had a 36-seat capacity, and was previously occupied by a three AA Rosette restaurant called the Oaks. Bosi had previously been head chef and won a Michelin star at the Overton Grange restaurant, just outside the town. He had intended to open a restaurant in Warwickshire, but found the premises too expensive and purchased a 25-year lease on the former Oaks property in Ludlow for £40,000. Within a year Hibiscus won its first Michelin star, and at the same time Overton Grange was downgraded before going into receivership. Working under Bosi at Hibiscus was sous chef Glynn Purnell, who left Hibiscus in 2003 to become head chef at Jessica's restaurant in Edgbaston. Hibiscus gained a second star in the 2004 Michelin Guide. In July 2006, Bosi and his wife Claire announced that they were intending to sell Hibiscus and open a new restaurant closer to London, or in the capital itself. Hibiscus closed in Ludlow in April 2007, with Bosi selling the site to fellow chef Alan Murchison for £247,500, but retaining the Hibiscus name for himself. The restaurant was renamed "Le Becasse" (sic), and underwent a £100,000 makeover before being re-opened under head chef Will Holland. In 2014, Murchison's company went into voluntary liquidation after running up debts of almost half a million pounds. Bosi completed the deal in June 2007 for a new site at 29 Maddox Street in London.
Sources: en.wikipedia.org
He defeated Čilić in his first match, but lost his final two matches and did not advance out of his round robin group. Zverev finished the year ranked No. 4, peaking at No. 3 right before the ATP Finals, and accumulated five ATP titles from just six finals.
The divisions between the elite and the lawless led to the formation of a Cossack army, beginning in 1667 under Stenka Razin, and ultimately to the failure of Razin's rebellion. Stenka Razin was born into an elite Cossack family, and had made many diplomatic visits to Moscow before organizing his rebellion. The Cossacks were Razin's main supporters, and followed him during his first Persian campaign in 1667, plundering and pillaging Persian cities on the Caspian Sea. They returned in 1669, ill and hungry, tired from fighting, but rich with plundered goods. Russia tried to gain support from the old Cossacks, asking the ataman, or Cossack chieftain, to prevent Razin from following through with his plans. But the ataman was Razin's godfather, and was swayed by Razin's promise of a share of expedition wealth. His reply was that the elite Cossacks were powerless against the band of rebels. The elite did not see much threat from Razin and his followers either, although they realized he could cause them problems with the Muscovite system if his following developed into a rebellion against the central government. Razin and his followers began to capture cities at the start of the rebellion, in 1669. They seized the towns of Tsaritsyn, Astrakhan, Saratov, and Samara, implementing democratic rule and releasing peasants from slavery as they went. Razin envisioned a united Cossack republic throughout the southern steppe, in which the towns and villages would operate under the democratic, Cossack style of government.
=== Metabolism === An adult body contains 22–26 grams of magnesium, with 60% in the skeleton, 39% intracellular (20% in skeletal muscle), and 1% extracellular. Serum levels are typically 0.7–1.0 mmol/L or 1.8–2.4 mEq/L. Serum magnesium levels may be normal even when intracellular magnesium is deficient. The mechanisms for maintaining the magnesium level in the serum are varying gastrointestinal absorption and renal excretion. Intracellular magnesium is correlated with intracellular potassium. Increased magnesium lowers calcium and can either prevent hypercalcemia or cause hypocalcemia depending on the initial level. Both low and high protein intake conditions inhibit magnesium absorption, as does the amount of phosphate, phytate, and fat in the gut. Unabsorbed dietary magnesium is excreted in feces; absorbed magnesium is excreted in urine and sweat.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.